Published in Vaccine Weekly, June 3rd, 2009
Toronto’s Arius Research, that made headlines last year in an all cash acquisition deal from Roche worth C$191 million, took top honours as company of the year. “With this significant deal with a major global pharmaceutical player, Arius is a successful example of the globally recognized leadership of Canadian private sector biotechnology research,” said BIOTECanada Chairman, Brad Thompson.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly